Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes
- PMID: 18493852
- DOI: 10.1007/s11064-008-9737-2
Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes
Abstract
We investigated the effect of the cAMP system on lipopolysaccharide (LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat primary astrocytes. Co-treatment with a cAMP analog, dibutyryl-cAMP (db-cAMP), or the cAMP elevating beta-adrenergic agonist, isoproterenol, concentration-dependently inhibited LPS-induced MMP-9 activity. In contrast, db-cAMP concentration-dependently increased tPA activity in both basal and LPS-stimulated rat primary astrocytes. To confirm the effect of cAMP on MMP-9 and tPA activity, we treated LPS-stimulated astrocytes with cAMP phosphodiesterase inhibitors, IBMX or rolipram, and they exhibited similar effects to db-cAMP, namely decreasing MMP-9 activity and increasing tPA activity. RT-PCR analysis of MMP-9 mRNA expression and MMP-9 promoter luciferase reporter assays revealed transcriptional upregulation by LPS stimulation and downregulation by db-cAMP. In contrast, the level of tPA mRNA expression was increased both by LPS and by cAMP treatment. Consistent with RT-PCR analysis, tPA promoter reporter assays showed increased activity by both LPS and cAMP stimulation. Interestingly, the level of mRNA encoding plasminogen activator inhibitor-1 (PAI-1) was increased by LPS stimulation and decreased back to control level after co-treatment with db-cAMP, suggesting that PAI-1 expression plays a major role in the regulation of tPA activity. To examine PKA involvement in the effects of db-cAMP on MMP-9 and tPA activity, we added the PKA inhibitors, H89 or rp-cAMP, along with db-cAMP, and they inhibited db-cAMP-mediated changes in tPA activity without affecting MMP-9 activity. These data suggest that cAMP differentially modulates MMP-9 and tPA activity through a mechanism related to PKA activation. The differential regulation of MMP-9 and tPA by the cAMP system may confer more sophisticated regulation of physiological processes, such as extracellular matrix remodeling and cell migration, by activated astrocytes.
Similar articles
-
Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1.Neurochem Int. 2011 Feb;58(3):423-33. doi: 10.1016/j.neuint.2010.12.020. Epub 2010 Dec 28. Neurochem Int. 2011. PMID: 21193004
-
Regulation of tissue plasminogen activator/plasminogen activator inhibitor-1 by hydrocortisone in rat primary astrocytes.J Neurosci Res. 2011 Jul;89(7):1059-69. doi: 10.1002/jnr.22619. Epub 2011 Mar 15. J Neurosci Res. 2011. PMID: 21412817
-
AUF-1 mediates inhibition by nitric oxide of lipopolysaccharide-induced matrix metalloproteinase-9 expression in cultured astrocytes.J Neurosci Res. 2006 Aug 1;84(2):360-9. doi: 10.1002/jnr.20895. J Neurosci Res. 2006. PMID: 16683234
-
Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells.Neurosci Lett. 2010 Jan 29;469(3):352-6. doi: 10.1016/j.neulet.2009.12.026. Epub 2009 Dec 21. Neurosci Lett. 2010. PMID: 20026244
-
Mechanisms of dexamethasone-mediated inhibition of cAMP-induced tPA expression in rat mesangial cells.Kidney Int. 2002 Sep;62(3):809-21. doi: 10.1046/j.1523-1755.2002.00538.x. Kidney Int. 2002. PMID: 12164863
Cited by
-
Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.Neurochem Res. 2010 Jul;35(7):976-85. doi: 10.1007/s11064-010-0141-3. Epub 2010 Feb 23. Neurochem Res. 2010. PMID: 20177776
-
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.J Cereb Blood Flow Metab. 2011 Nov;31(11):2119-34. doi: 10.1038/jcbfm.2011.127. Epub 2011 Aug 31. J Cereb Blood Flow Metab. 2011. PMID: 21878948 Free PMC article. Review.
-
The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases.Br J Pharmacol. 2012 Jun;166(4):1225-43. doi: 10.1111/j.1476-5381.2012.01917.x. Br J Pharmacol. 2012. PMID: 22364165 Free PMC article. Review.
-
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact.Brain. 2009 Aug;132(Pt 8):2219-30. doi: 10.1093/brain/awp162. Epub 2009 Jul 2. Brain. 2009. PMID: 19574439 Free PMC article.
-
The Effector Protein BPE005 from Brucella abortus Induces Collagen Deposition and Matrix Metalloproteinase 9 Downmodulation via Transforming Growth Factor β1 in Hepatic Stellate Cells.Infect Immun. 2015 Dec 14;84(2):598-606. doi: 10.1128/IAI.01227-15. Print 2016 Feb. Infect Immun. 2015. PMID: 26667834 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous